PD-1 inhibitors, such as nivolumab and pembrolizumab, are used for the immunotherapy of metastatic, resistant non-small-cell lung cancer and metastatic melanoma patients. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.